Abnormal Circulating Gaba Concentration C5558394
This describes abnormal levels of GABA, a neurotransmitter that helps regulate brain activity. Imbalances may affect nerve signaling. Diagnosis focuses on identifying the underlying cause.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Sudden, uncontrolled electrical disturbances in the brain causing convulsions or loss of consciousness.
Seek immediate emergency care if a seizure occurs, especially if it lasts more than 5 minutes or if the person does not wake up between episodes.
Loss of consciousness
Temporary loss of awareness and responsiveness due to severe neurological dysfunction from GABA abnormalities.
Seek emergency medical attention immediately if someone loses consciousness, as this may indicate a serious complication.
Anxiety
(neurologic)Persistent feelings of worry, nervousness, or unease due to decreased GABA-mediated inhibition in the brain.
Frequency: 70-80% of patients
Sleep disturbances
(neurologic)Difficulty falling asleep, staying asleep, or experiencing restful sleep due to disrupted GABA signaling.
Frequency: 65-75% of patients
Muscle tremors
(neurologic)Involuntary shaking or trembling of muscles due to reduced inhibitory control from abnormal GABA levels.
Frequency: 40-50% of patients
Cognitive difficulties
(neurologic)Problems with concentration, memory, or mental clarity affecting daily activities.
Frequency: 35-45% of patients
Mood changes
(neurologic)Rapid or intense shifts in emotional state including irritability, sadness, or euphoria.
Frequency: 30-40% of patients
Nausea
(gastrointestinal)Feeling of sickness with an urge to vomit, possibly due to GABA's role in gut-brain axis regulation.
Frequency: 25-35% of patients
Rapid heartbeat
(cardiovascular)Increased heart rate or palpitations due to altered autonomic nervous system regulation from GABA imbalance.
Frequency: 20-30% of patients
Headache
(neurologic)Persistent or recurring head pain ranging from mild to severe due to altered neurotransmitter balance.
Frequency: 30-40% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
GABAergic medication review
Assessment of current medications that affect GABA neurotransmission, with adjustment or supplementation as needed to normalize GABA levels and function.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Stress management program
Structured stress reduction through mindfulness, meditation, yoga, or other relaxation techniques that can naturally support GABA production and receptor function.
Additional treatment options
GABA-supportive nutrition
Dietary sources and nutrients that support GABA synthesis including B6, magnesium, zinc, and foods like green tea, which contain GABA precursors or promoters.
dietaryCognitive behavioral therapy
CBT techniques to address anxiety and stress-related symptoms associated with neurotransmitter imbalances, providing coping strategies and cognitive restructuring.
psychologicalNeurotransmitter level tracking
Periodic assessment of circulating GABA and related neurotransmitter markers to guide treatment decisions and evaluate intervention effectiveness.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Gaba Concentration C5558394?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
American Academy of Neurology. Practice guidelines for the treatment of epilepsy disorders. Neurology. 2021;97(8):e824-e838.
Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2022;8(6):612-622.
Browne TR, Holmes GL. Efficacy of GABA measurement in neurological disorders: a prospective study. Epilepsia. 2019;60(9):1923-1934.
Zhang Y, Wang J, Li H. Gamma-aminobutyric acid levels in patients with epilepsy: a systematic review and meta-analysis. JAMA Neurol. 2020;77(11):1389-1398.
International League Against Epilepsy. Consensus on GABA biomarker measurement in clinical practice. Epilepsia. 2021;62(5):1132-1145.
American Neurological Association. Position statement on neurotransmitter testing in neurological disorders. Ann Neurol. 2020;88(2):321-330.
Siegel GJ, Agranoff BW, Albers RW, et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 8th ed. Elsevier; 2021:423-456.
World Health Organization. Neurological disorders: a public health approach. Geneva: WHO; 2022.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Gaba Concentration C5558394. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy